CN1119152C - Injection for treating tumor in digestive system and its application - Google Patents
Injection for treating tumor in digestive system and its application Download PDFInfo
- Publication number
- CN1119152C CN1119152C CN98118119A CN98118119A CN1119152C CN 1119152 C CN1119152 C CN 1119152C CN 98118119 A CN98118119 A CN 98118119A CN 98118119 A CN98118119 A CN 98118119A CN 1119152 C CN1119152 C CN 1119152C
- Authority
- CN
- China
- Prior art keywords
- injection
- digestive system
- cell
- isotonic solution
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to an injection for treating tumors in a digestive system and applications thereof. In the prior art, cell toxic medicines are used for treating tumors. The injection of the present invention comprises an isotonic solution containing 1/1000 to 17/1000 of arsenious acid. For the applications in medicines for treating the tumors in the digestive system, 10 ml of injection is added to 500 ml of isotonic solution for intravenous perfusion. The injection is used for treating the tumors in the digestive system with no toxic side effect on normal cells and has a clinic effective rate of 75 to 92%.
Description
Technical field: the present invention relates to a kind of injection and the application of this product in the medicine of treatment digestive system tumor thereof that contains arsenious acid.
Background technology: Ministry of Public Health in 1992 sends in " about the notice of further reinforcement treatment and prevention of tumour work " to be pointed out, the annual pathogenesis of cancer of current China is about 1,600,000, and the annual number because of cancer mortality in the whole nation rises to more than 130 ten thousand from 700,000.At present, the non-surgical treatment of cancer is that chemotherapy is main, generally adopts cell toxicant type, and from world wide, the research of nearest novel drugs concentrates on the combination of known active drug and the medicine close with the known drug structure to a great extent.Particularly concentrate on the research of anthracene nucleus medicament and second filial generation platinum-like compounds.This is because develop in the field of similar that not only risk is little, difficulty is low, obtain the probability height of achievement in research, is exactly illustration such as succeeding in developing of epirubicin and carboplatin.But along with exploitation these years, these are more and more littler in the field opened up that the periphery in prior art field is studied, the difficulty of development cancer therapy drug is increasing, and research cycle is more and more longer, and is expensive more and more higher, because structure is close, is difficult to the expectation curative effect and is greatly improved.Therefore, many scholars think that the research of cancer therapy drug should explore new field, and it is faced with new theory, and the challenge of new technique.
Arsenious acid is considered to a kind of carcinogen and poison always for many years, can the trigger cell metabolism disorder, and controlled use.
Summary of the invention:
The object of the present invention is to provide a kind of treat digestive system tumor injection and the application in the medicine of this field disease of preparation thereof, impel cancerous cell itself that apoptosis takes place, reach and reduce the healthy cell infringement, the effect of treatment cancer.
The object of the present invention is achieved like this:
First scheme: (product invention) a kind of treatment digestive system tumor injection, its composition comprises: isotonic solution comprises arsenious acid 1/1000-17/1000, by weight in the described isotonic solution.
Alternative plan: the application of product in preparation treatment digestive system tumor medicine that (purposes invention) is above-mentioned.
During use: described treatment digestive system tumor injection 10ml is configured in the 500ml isotonic solution, as such tumor patient intravenous drip medicine.
The invention has the advantages that:
1. break through traditional view, developing new drug and new application
The present invention has broken through the traditional idea of using cell toxicant kind anti-cancer drugs product treatment cancer and the traditional view that arsenious acid causes cancer, has opened up and has adopted arsenious acid to impel the frontier of cancer cell-apoptosis as differentiating inducer.Lay a good foundation for seeking new cancer therapy drug series.
2. medical effect is obvious
Utilize arsenious acid to induce and impel cancer cell-apoptosis in the entity tumor of digestive system.When the fluorescent labeling that makes cancerous cell is positive, use this product cancerous cell the poly-group of fluorescence string to occur, cell volume obviously reduces.
3. clinical practice has the science test basis
The international academic community expert is up-to-date to be thought, the unrestricted growth of tumor may be because it can not be died by spontaneous accent, is not that its normal cell proliferation is fast.Laboratory tests prove that there is the bad state of apoptosis really in cancer cell.Warp is to the survival genes test of (suppressing apoptotic oncogene to being acknowledged as the energy specificity), it is positive that patient more than 75% exists the Bel cancerous cell to express, through in vitro tests to cancerous cell, it is 0.30 μ g/ml that the present invention has the meansigma methods of stronger cytotoxicity IG50 value for cancerous cell, the meansigma methods of IC50 value that has the cancerous cell of HL60 for the typical case is 0.45 μ g/ml, is 0.35 μ g/ml for the meansigma methods of the IC50 value of the gene cancerous cell that typically has K562.As seen the present invention can obviously regulate and control relevant cancer cell-apoptosis gene, the apoptosis of control cancer cell and induce differentiation, to change cancerous tissue, and make it to finish Normocellular apoptosis and produce qualitative change, simultaneously by and impel cancerous cell quick apoptosis, induce differentiation to make it quantitatively to reduce rapidly.Therefore, by the clinical practice for patients such as esophageal carcinoma, intestinal cancer, cancer of pancreas, up to 75-92%, this product has been reported new drug for the clinical effective rate of such case in the present invention, specifies through relevant ministries and commissions of country and carries out clinical verification.
4. only cancerous cell is worked, do not damage normal cell, curative effect is rapid
Existing chemotherapeutics is a cytotoxic drug, the poor selectivity of pair cell, and whether be cancerous cell, kill and wound without exception if being regardless of, therefore the toxic and side effects that health is brought is big.Use the solution of the present invention only the bad cancerous cell of apoptosis to be worked, therefore the toxic and side effects of existing cytotoxic drug can take place hardly to normal cell.Therefore, overcome general chemotherapy medicine because of the human normal cell being damaged greatly the shortcoming that can not use continuously.General patient just can be alleviated behind trial edition invention product in average 60 days fully.
5. have no drug resistance
Through clinical use, cancerous cell has been adjusted apoptosis function.And can not produce the normal chemical sproof Signs that occurs of common use chemotherapeutics.
6. low price, high curative effect
Product price of the present invention only is 1/3 even 1/20 of a similar chemotherapeutics, be a kind of low toxicity, at a low price, the new drug of high curative effect.
Embodiment 1:(product invention)
A kind of treatment digestive system tumor injection that directly carries out intravenous drip, its composition comprises: (the following any amount of 20 grams all can more than 1 gram to add 1 gram in a certain amount of water for injection, as 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20 grams and interval decimal thereof) medical arsenous acid anhydride, heating, make it to be dissolved into arsenious acid, the NaCl or the glucose that add milliosmolaritys such as being fit to, add water to prescribed concentration, make the isotonic solution that contains arsenious acid, comprise arsenious acid 1/10000-1/1000 (wherein not comprising 1/1000) or 1/1000000-17/1000 any content wherein in the described isotonic solution.This isotonic solution is to be made of glucose, or by etc. ooze normal saline and constitute, also can mix and constitute by two kinds of isotonic solutions of g/s (NaCl).Other process conditions should meet the pharmaceutical production requirement.The preparation that concentration is low often more is applicable to the situation that short-distance transport does not need secondary dilution to use, and perhaps need select for use at baby, child and weakling.The preparation of high concentration is easy to transportation, but when directly using this injection drop of maximum concentration, serviceability temperature must not be hanged down 16 ℃.
Embodiment 2:(product invention)
A kind of treatment digestive system tumor injection that directly carries out intravenous drip, its composition comprises: (the following any amount of 20 grams all can more than 1 gram to add 1 gram in a certain amount of water for injection, see that embodiment 1 is described) medical arsenous acid anhydride, heating makes it to be dissolved into arsenious acid, adds the NaCl glucose of milliosmolaritys such as being fit to, add water to prescribed concentration, make the isotonic solution that contains arsenious acid, comprise arsenious acid 1/1 in the described isotonic solution, 000-17/1000.This isotonic solution is to be made of glucose, or by etc. ooze normal saline and constitute, also can mix and constitute by two kinds of isotonic solutions of g/s (NaCl).Other process conditions should meet the pharmaceutical production requirement.The preparation that concentration is low often more is applicable to the situation that short-distance transport does not need secondary dilution to use, and perhaps need select for use at baby, child and weakling.The preparation of high concentration is easy to transportation, but when directly using this injection drop of maximum concentration, serviceability temperature must not be hanged down 16 ℃.
The invention of embodiment 3:(purposes) embodiment 1, the application of embodiment 2 described products in preparation treatment digestive system tumor medicine.
During use, described treatment digestive system tumor injection 10ml is configured in the 500ml isotonic solution, is used as the medicine of such tumor patient intravenous drip.The dead point amount of being grown up every day when using is a 0.008-0.07 gram (in As+++).Being lower than 0.008 gram effect can obviously descend, and is higher than the obvious non-linear increasing of 0.07 gram side effect, and per 4 weeks are a course of treatment, and clinical use amount should be according to weight in patients, body constitution by doctor's advice.
Claims (2)
1. treat the digestive system tumor injection for one kind, its composition comprises: isotonic solution is characterized in that: comprise arsenious acid 1/1 in the described isotonic solution, 000-17/1000 is in weight ratio.
2. the described application of product in preparation treatment digestive system tumor medicine that contains arsenious acid of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98118119A CN1119152C (en) | 1998-08-02 | 1998-08-02 | Injection for treating tumor in digestive system and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98118119A CN1119152C (en) | 1998-08-02 | 1998-08-02 | Injection for treating tumor in digestive system and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1243706A CN1243706A (en) | 2000-02-09 |
| CN1119152C true CN1119152C (en) | 2003-08-27 |
Family
ID=5225892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98118119A Expired - Fee Related CN1119152C (en) | 1998-08-02 | 1998-08-02 | Injection for treating tumor in digestive system and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1119152C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009898A (en) * | 2002-04-10 | 2005-06-20 | Korea Microbiological Lab Ltd | Pharmaceutical composition comprising arsenite for the treatment of malignancy. |
-
1998
- 1998-08-02 CN CN98118119A patent/CN1119152C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 《口腔颌面外科杂志》8,(4) 1998-04-30 王跃平等三氧化二砷在肿瘤治疗中的作用及展望 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1243706A (en) | 2000-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1119152C (en) | Injection for treating tumor in digestive system and its application | |
| CN1119153C (en) | Injection for treating tumor in respiratory system and its application | |
| CN1114416C (en) | Injection for treating gynecologic tumor and lymphomatosis and its application | |
| CN109876154A (en) | The nanoparticle preparation of a kind of polysaccharides modification and its antitumor activity | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN102697757A (en) | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy | |
| CN104327068B (en) | Anticancer analgesic selenium-containing compound and preparation method and application thereof | |
| CN113384698A (en) | Self-assembled nano-medicament for synergetic chemotherapy/acousto-photodynamic therapy and application thereof | |
| CN104055786B (en) | The application in preparation preventing and treating tumour medicine of medicagenic acid-3-O-β-D-pyranglucoside, medicagenic acid and salt thereof | |
| CN1269487C (en) | Arsenic trioxide oral liquid and its preparation process | |
| CN101156841B (en) | An antineoplastic new use of biphenyl acetic acid and its salt | |
| CN102391499B (en) | Preparation method of polymer for quickly releasing active components of masticinic acid under exciting of reduction | |
| CN1771984B (en) | New use of extracellular polysaccharide of halophilous aphanothece | |
| CN103012672A (en) | 5-fluorouracil copolymer with anti-tumor activity and preparation method of 5-fluorouracil copolymer | |
| CN102824334A (en) | Anti-cancer drug | |
| CN102228427A (en) | Vitexin glucoside injection and preparation method thereof | |
| CN101797242A (en) | Application of cysteamine in preparing medicine for treating cancer | |
| CN108484661A (en) | One kind six vanadic acid-Beta-alanine tert-butyl ester derivative and the preparation method and application thereof | |
| CN108546286A (en) | A kind of small peptide PR20 that can specifically promote pancreatic cancer cell death and its derivative and application | |
| CN102068588B (en) | Chinese medicinal preparation for treating hepatopathy and preparation method thereof | |
| WO2021196086A1 (en) | Method for inhibiting cell activity by means of intracellular polymerization and pro-drug implementing method | |
| CN102008539A (en) | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN1243708A (en) | Injection for treating thrombocytopenic purpura and its application | |
| CN106668061B (en) | A kind of anticancer pharmaceutical composition containing cis-platinum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030827 Termination date: 20170802 |